| 厄洛替尼联合抗血管生成药物对比厄洛替尼单药一线治疗EGFR突变晚期非小细胞肺癌的疗效 |
| |
| 引用本文： | 冯卫能,邓秋梅. 厄洛替尼联合抗血管生成药物对比厄洛替尼单药一线治疗EGFR突变晚期非小细胞肺癌的疗效[J]. 循证医学, 2020, 20(1): 53-57. DOI: 10.12019/j.issn.1671-5144.2020.01.012 |
| |
| 作者姓名： | 冯卫能 邓秋梅 |
| |
| 作者单位： | 1. 佛山市第一人民医院头颈胸肿瘤内科,广东佛山 528000; 2. 广东省人民医院肿瘤中心, 广东省医学科学院、广东省肺癌研究所、广东省心血管病研究所, 广州510080 |
| |
| 摘 要： |
|
| 关 键 词： | 非小细胞肺癌 EGFR敏感突变 EGFR-TKI联合抗血管生成 |
The Efficacy of Erlotinib Combined with Anti-Angiogenesis Treatment in Comparison with Erlotinib Alone as First-Line Treatment of EGFR-Mutated Advanced Non-Small Cell Lung Cancer |
| |
| FENG Wei-neng,DENG Qiu-mei. The Efficacy of Erlotinib Combined with Anti-Angiogenesis Treatment in Comparison with Erlotinib Alone as First-Line Treatment of EGFR-Mutated Advanced Non-Small Cell Lung Cancer[J]. The Journal of Evidence-Based Medicine, 2020, 20(1): 53-57. DOI: 10.12019/j.issn.1671-5144.2020.01.012 |
| |
| Authors: | FENG Wei-neng DENG Qiu-mei |
| |
| Affiliation: | Reviewer’s address：Department of Head and Neck/Thoracic Oncology, The First People’s Hospital of Foshan, Guangdong Foshan 528000, China |
| |
| Abstract: | |
| |
| Keywords: | non-small-cell lung cancer EGFR positive EGFR-TKI combined with anti-angiogenesis treatment |
|
| 点击此处可从《循证医学》浏览原始摘要信息 |
|
点击此处可从《循证医学》下载免费的PDF全文 |
